Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16136051rdf:typepubmed:Citationlld:pubmed
pubmed-article:16136051lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:16136051lifeskim:mentionsumls-concept:C0024204lld:lifeskim
pubmed-article:16136051lifeskim:mentionsumls-concept:C1513276lld:lifeskim
pubmed-article:16136051lifeskim:mentionsumls-concept:C1708790lld:lifeskim
pubmed-article:16136051lifeskim:mentionsumls-concept:C1880916lld:lifeskim
pubmed-article:16136051lifeskim:mentionsumls-concept:C1569815lld:lifeskim
pubmed-article:16136051pubmed:issue6lld:pubmed
pubmed-article:16136051pubmed:dateCreated2005-10-13lld:pubmed
pubmed-article:16136051pubmed:abstractTextThe monoclonal antibody D2-40 is a specific lymphatic endothelial markers and D2-40 staining have been applicable to evaluate lymphatic invasion in various malignant neoplasms. In the present study, we investigated lymph node micrometastasis determined by immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR) in all dissected lymph nodes obtained from 80 patients with node-negative gastric cancer, and analysed the relationship between micrometastasis and clinicopathological findings including lymphatic invasion of the resected primary tumour using D2-40 immunohistochemical staining. The incidence of micrometastasis determined by IHC and RT-PCR was 11.3% (nine out of 80) and 31.3% (25 out of 80), respectively. Although haematoxylin-eosin (HE) staining revealed lymphatic invasion in 11.3% (nine out of 80) of patients, D2-40 staining uncovered new invasion in 23.8% (19 out of 80) of patients. In the diagnosis of HE and D2-40 staining, the incidence of micrometastasis was significantly higher in patients with lymphatic invasion than in those without lymphatic invasion (P=0.0150 and P<0.0001, respectively). Micrometastasis correlated more closely with D2-40 than with HE staining. We demonstrated a high incidence of micrometastasis and lymphatic invasion and a correlation between them even in pN0 gastric cancer. When planning less invasive treatment, the presence of such occult cancer cells should be considered.lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:languageenglld:pubmed
pubmed-article:16136051pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:citationSubsetIMlld:pubmed
pubmed-article:16136051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16136051pubmed:statusMEDLINElld:pubmed
pubmed-article:16136051pubmed:monthSeplld:pubmed
pubmed-article:16136051pubmed:issn0007-0920lld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:IshigamiSSlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:ArimaHHlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:YanagidaSSlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:NatsugoeSSlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:AikouTTlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:HokitaSSlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:MatakiYYlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:UenosonoYYlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:HanQiQlld:pubmed
pubmed-article:16136051pubmed:authorpubmed-author:ArigamiTTlld:pubmed
pubmed-article:16136051pubmed:issnTypePrintlld:pubmed
pubmed-article:16136051pubmed:day19lld:pubmed
pubmed-article:16136051pubmed:volume93lld:pubmed
pubmed-article:16136051pubmed:ownerNLMlld:pubmed
pubmed-article:16136051pubmed:authorsCompleteYlld:pubmed
pubmed-article:16136051pubmed:pagination688-93lld:pubmed
pubmed-article:16136051pubmed:dateRevised2010-9-20lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:meshHeadingpubmed-meshheading:16136051...lld:pubmed
pubmed-article:16136051pubmed:year2005lld:pubmed
pubmed-article:16136051pubmed:articleTitleLymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer.lld:pubmed
pubmed-article:16136051pubmed:affiliationDepartment of Surgical Oncology and Digestive Surgery, Field of Oncology, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. arigami@m.kufm.kagoshima-u.ac.jplld:pubmed
pubmed-article:16136051pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16136051pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16136051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16136051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16136051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16136051lld:pubmed